Skip to main content
Home
Search
Search for Disease
NEW
Search for Combinatorial Drug (CBD)
NEW
Search for Repurposed Drug (RPD)
NEW
Search for Drug Off-target (DOT)
NEW
Search for Drug
Search for Drug Therapeutic Target (DTT)
Search for Drug Transporter (DTP)
Search for Drug-Metabolizing Enzyme (DME)
Drug Structure Similarity Search
Molecule Sequence Similarity Search
Download
Help
About
Drug Information
Drug General Information
Drug ID
D0K4TI
Former ID
DNC003985
Drug Name
5-Hexyl-5-phenyl-pyrimidine-2,4,6-trione
Drug Type
Small molecular drug
Indication
Discovery agent
Investigative
[
526040
]
Formula
C16H20N2O3
Canonical SMILES
CCCCCCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2
InChI
1S/C16H20N2O3/c1-2-3-4-8-11-16(12-9-6-5-7-10-12)13(19)17-15(21)18-14(16)20/h5-7,9-10H,2-4,8,11H2,1H3,(H2,17,18,19,20,21)
InChIKey
LWBGXTORWSRDHX-UHFFFAOYSA-N
PubChem Compound ID
49292
Target and Pathway
Target(s)
MMP-9
Target Info
Inhibitor
[
526040
]
72 kDa type IV collagenase
Target Info
Inhibitor
[
526040
]
KEGG Pathway
TNF signaling pathway
Leukocyte transendothelial migration
Estrogen signaling pathway
Hepatitis B
Pathways in cancer
Transcriptional misregulation in cancer
Proteoglycans in cancer
MicroRNAs in cancer
Bladder cancerhsa04670:Leukocyte transendothelial migration
GnRH signaling pathway
Bladder cancer
NetPath Pathway
ID Signaling Pathway
TWEAK Signaling Pathway
Leptin Signaling Pathway
TNFalpha Signaling PathwayNetPath_22:Leptin Signaling Pathway
TCR Signaling Pathway
PANTHER Pathway
Alzheimer disease-presenilin pathway
Plasminogen activating cascade
CCKR signaling map STP00004:Alzheimer disease-presenilin pathway
Pathway Interaction Database
LPA receptor mediated events
Plasma membrane estrogen receptor signaling
Osteopontin-mediated events
Validated transcriptional targets of AP1 family members Fra1 and Fra2
Validated targets of C-MYC transcriptional activation
CXCR4-mediated signaling events
amb2 Integrin signaling
Syndecan-4-mediated signaling events
AP-1 transcription factor network
Urokinase-type plasminogen activator (uPA) and uPAR-mediated signaling
Syndecan-1-mediated signaling events
Regulation of nuclear beta catenin signaling and target gene transcription
FGF signaling pathwaylysophospholipid_pathway:LPA receptor mediated events
Angiopoietin receptor Tie2-mediated signaling
Direct p53 effectors
ATF-2 transcription factor network
FOXM1 transcription factor network
Syndecan-2-mediated signaling events
Reactome
Collagen degradation
Degradation of the extracellular matrix
Activation of Matrix Metalloproteinases
Assembly of collagen fibrils and other multimeric structures
EPH-ephrin mediated repulsion of cellsR-HSA-1442490:Collagen degradation
Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs)
EPH-ephrin mediated repulsion of cells
WikiPathways
Endochondral Ossification
IL1 and megakaryotyces in obesity
Mammary gland development pathway - Involution (Stage 4 of 4)
Activation of Matrix Metalloproteinases
Degradation of collagen
Spinal Cord Injury
AGE/RAGE pathway
TWEAK Signaling Pathway
Angiogenesis
Osteopontin Signaling
Matrix MetalloproteinasesWP2769:Activation of Matrix Metalloproteinases
Matrix Metalloproteinases
References
Ref 526040
Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.
Ref 526040
Bioorg Med Chem Lett. 2001 Apr 23;11(8):969-72.Novel 5,5-disubstitutedpyrimidine-2,4,6-triones as selective MMP inhibitors.